Home Featured Page 33

Featured

Latest

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Zach Leary – Your Extraordinary Mind

Psychedelic Funding Update: Q1 2025

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and...

High Hopes in the Mile High City: Inside Colorado’s First Licensed...

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

Oakland Psychedelic Conference

Kayse Gehret – The Modern Guide: Microdosing, Facilitation & Community

The VA, Psychedelics, and the Future of Mental Health: A Conversation...

EDITOR PICKS

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant...

The Psychedelic Practitioner Issue 5: Groups in Practice

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Zach Leary – Your Extraordinary Mind

Psychedelic Funding Update: Q1 2025

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and...

High Hopes in the Mile High City: Inside Colorado’s First Licensed...

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

Psychedelic Science 2025

Oakland Psychedelic Conference

Kayse Gehret – The Modern Guide: Microdosing, Facilitation & Community

LP Giobi – Livestream

The VA, Psychedelics, and the Future of Mental Health: A Conversation...

EDITOR PICKS

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant...

The Psychedelic Practitioner Issue 5: Groups in Practice

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY